Longitudinal prescribing patterns for psychoactive medications in community-based individuals with developmental disabilities: Utilization of pharmacy records

Journal of Intellectual Disability Research

Volumn 48, Issue 6, 2004, Pages 563-571

  Lott, Ira T ^a,c   McGregor, M ^a,c   Engelman, L ^a,c   Touchette, P ^a,c   Tournay, A ^a,c   Sandman, C ^b,c   Fernandez, G ^b,c   Plon, L ^a   Walsh, D ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NONE   (United States)

Author keywords

Antipsychotic medications; Longitudinal study; Polypharmacy; Prescribing patterns; Psychoactive medications

Indexed keywords

AMANTADINE; AMFEBUTAMONE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZATROPINE; CARBAMAZEPINE; CLOMIPRAMINE; CLONAZEPAM; CLONIDINE; DIAZEPAM; FLUOXETINE; FLUPHENAZINE; HALOPERIDOL; LAMOTRIGINE; LORAZEPAM; NEFAZODONE; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PERPHENAZINE; PROPRANOLOL; PSYCHOSTIMULANT AGENT; PSYCHOTROPIC AGENT; RISPERIDONE; SERTRALINE; THIORIDAZINE; TOPIRAMATE; TRAZODONE; UNINDEXED DRUG; VALPROIC ACID;

ACCESS TO INFORMATION; ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CHILD; COMMUNITY CARE; CONTROLLED STUDY; DATA ANALYSIS; DEVELOPMENTAL DISORDER; FEMALE; HUMAN; INTELLECTUAL IMPAIRMENT; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MENTAL DISEASE; PHARMACY; POLYPHARMACY; PRESCRIPTION; PREVALENCE;

ADULT; CHILD; COGNITION DISORDERS; COMMUNITY MENTAL HEALTH SERVICES; DEVELOPMENTAL DISABILITIES; DRUG UTILIZATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MEDICAL RECORDS; MIDDLE AGED; POLYPHARMACY; PRESCRIPTIONS, DRUG; PREVALENCE; PSYCHOTIC DISORDERS; PSYCHOTROPIC DRUGS;

EID: 4544241920     PISSN: 09642633     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2788.2004.00625.x     Document Type: Article

References (38)

1. Advokat C. D., Mayville E. A. & Matson J. L. (2000) Side effect profiles of atypical antipsychotics, typical antipsychotics, or no psychotropic medications in persons with mental retardation. Research and Developmental Disability 21, 75-84.
2. Aman M. G., De Smedt G., Derivan A., Lyons B. & Findling R. L. (2002) Double-blind, placebo-controlled study of resperidone for the treatment of disruptive behaviors in children with subaverage intelligence. American Journal of Psychiatry 159, 1337-46.
3. Anderson G. M., Beers M. H. & Kerluke K. (1997) Auditing prescription practice using explicit criteria and computerized drug benefit claims data. Journal of Evaluation Clinical Practice 3, 283-94.
4. Arvio M. & Sillanpaa M. (2003) Prevalence, etiology and comorbidity of severe and profound intellectual disability in Finland. Journal of Intellect Disability Research 47, 108-12.
5. Buck J. A. & Sprague R. L. (1989) Psychotropic medication of mentally retarded residents in community long-term care facilities. American Journal of Mental Retardation 93, 617-23.
6. Buitelaar J. K., van der Gaag R. J., Cohen-Kettenis P. & Melman C. T. (2001) A randomized controlled trial of resperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. Journal of Clinical Psychiatry 62, 239-48.
7. Burd L., Fisher W., Vesely B. N., Williams M., Kerbeshian J. & Leech C. (1991) Prevalence of psychoactive drug use among North Dakota group home residents. American Journal of Mental Retardation 96, 119-26.
8. Burd L., Williams M., Klug M. G., Fjelstad K., Schimke A. & Kerbeshian J. (1997) Prevalence of psychotropic and anticonvulsant drug use among North Dakota group home residents. Journal of Intellect Disability Research 41, 488-94.
9. Chong S. A., Remington G. J., Lee N. & Mahendran R. (2000) Contrasting clozapine prescribing patterns in the east and west? Annals of Academy of Medical Singapore 29, 75-8.
10. Connor D. F., Ozbayrak K. R., Harrison R. J. & Melloni R. H. Jr (1998) Prevalence and patterns of psychotropic and anticonvulsant medication use in children and adolescents referred to residential treatment. Journal of Child and Adolescent Psychopharmacology 8, 27-38.
11. Cormack K. F., Brown A. C. & Hastings R. P. (2000) Behavioural and emotional difficulties in students attending schools for children and adolescents with severe intellectual disability. Journal of Intellect Disability Research 44, 124-9.
12. Dekker M. C., Koot H. M., van der Ende J. & Verhulst F. C. (2002) Emotional and behavioral problems in children and adolescents with and without intellectual disability. Journal of Child Psychological Psychiatry 43, 1087-98.
13. Donoghue J. (2000) Antidepressant use patterns in clinical practices: comparisons among tricyclic antidepressants and selective serotonin reuptake inhibitors. Acta Psychiatrica Scandinavica Supplementum 403, 57-61.
14. Emerson E. (2003) Prevalence of psychiatric disorders in children and adolescents with and without intellectual disability. Journal of Intellect Disability Research 47, 51-8.
15. Friedlander R., Lazar S. & Klancnik J. (2001) Atypical antipsychotic use in treating adolescents and young adults with developmental disabilities. Canadian Journal of Psychiatry 46, 741-5.
16. Golden A. G., Preston R. A., Barnett S. D., Llorente M., Hamdan K. & Silverman M. A. (1999) Inappropriate medication prescribing in homebound older adults. Journal of the American Geriatrics Society 47, 948-53.
17. Hardan A. & Sahl R. (1999) Suicidal behavior in children and adolescents with developmental disorders. Research and Developmental Disability 20, 287-96.
18. Harper D. C., Wadsworth J. S. & Michael A. L. (1989) Psychotropic drug use in older developmentally disabled with behavioral difficulties. Research and Developmental Disability 10, 53-60.
19. Kerr E. A., McGlynn E. A., VanVorst K. A. & Wickstrom S. L. (2000) Measuring antidepressant prescribing practice in a health care system using administrative data: implications for quality measurement and improvement. The Joint Commission Journal on Quality Improvement 26, 203-16.
20. Linden M., Lecrubier Y., Bellantuono C., Benkert O., Kisely S. & Simon G. (1999). The prescribing of psychotropic drugs by primary care physicians: an international collaborative study. Journal of Clinical Psychopharmacology 19, 132-40.
21. Nichol M. B., Stimmel G. L. & Lange S. C. (1995) Factors predicting the use of multiple psychotropic medications. Journal of Clinical Psychiatry 56, 60-6.
22. Nottestad J. A. & Linaker O. M. (1999) Psychiatric health needs and services before and after complete deinstitutionalization of people with intellectual disability. Journal of Intellect Disability Research 43, 523-30.
23. O'Brien G. (2002) Dual diagnosis in offenders with intellectual disability: setting research priorities: a review of research findings concerning psychiatric disorder (excluding personality disorder) among offenders with intellectual disability. Journal of Intellect Disability Research 46, 21-30.
24. Patel N. C., Crismon M. L., Rush A. J. & Frances A. (2001) Practitioner versus medication-expert opinion on psychiatric pharmacotherapy of mentally retarded patients with mental disorders. American Journal of Health-Systematic Pharmacy 58, 1724-9.
25. Safer D. J. (1997) Changing patterns of psychotropic medications prescribed by child psychiatrists in the 1990s. Journal of Child Adolescent Psychopharmacology 7, 267-74.
26. Santosh P. J. & Baird G. (1999) Psychopharmacotherapy in children and adults with intellectual disability. Lancet 354, 233-42.
27. Sclar D. A., Robinson L. M., Skaer T. L. & Galin R. S. (1998) Trends in the prescribing of antidepressant pharmacotherapy: office-based visits, 1990-1995. Clinical Therapy 20, 871-84.
28. Sherrard J., Tonge B. J. & Ozanne-Smith J. (2002) Injury risk in young people with intellectual disability. Journal of Intellect Disability Research 46, 6-16.
29. Simeon J., Milin R. & Walker S. (2002) A retrospective chart review of resperidone use in treatment-resistant children and adolescents with psychiatric disorders. Progress in Neuropsychopharmacological Biology Psychiatry 26, 267-75.
30. Singh N. N., Ellis C. R. & Wechsler H. (1997) Psychopharmacoepidemiology of mental retardation: 1966-1995. Journal of Child Adolescent Psychopharmacology 7, 255-66.
31. Spreat S. & Conroy J. (1998) Use of psychotropic medications for persons with mental retardation who live in Oklahoma nursing homes. Psychiatric Services 49, 510-2.
32. Spreat S., Conroy J. & Jones J. C. (1997) Use of psychotropic medication in Oklahoma: a statewide survey. American Journal of Mental Retardation 102, 80-5.
33. Stolker J. J., Heerdink E. R., Leufkens H. G., Clerkx M. G. & Nolen W. A. (2001) Determinants of multiple psychotropic drug use in patients with mild intellectual disabilities or borderline intellectual functioning and psychiatric or behavioral disorders. General Hospital Psychiatry 23, 345-9.
34. Stolker J. J., Koedoot P. J., Heerdink E. R., Leufkens H. G. & Nolen W. A. (2002) Psychotropic drug use in intellectually disabled group-home residents with behavioural problems. Pharmacopsychiatry 35, 19-23.
35. Swadi H. & Eapen V. (2000) A controlled study of psychiatric morbidity among developmentally disabled children in the United Arab Emirates. Journal of Tropical Pediatrics 46, 278-81.
36. Tong B. & Einfeld S. (2000) The trajectory of psychiatric disorders in young people with intellectual disabilities. Journal of Psychiatry 34, 80-4.
37. Van Bellinghen M. & De Troch C. (2001) Resperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: a double-blind, placebo-controlled pilot trial. Journal of Child Adolescent Psychopharmacology 11, 5-13.
38. Zarcone J. R., Hellings J. A., Crandall K., Reese R. M., Marquis J., Fleming K., Shores R., Williams D. & Schroeder S. R. (2001) Effects of resperidone on aberrant behavior of persons with developmental disabilities: I. A double-blind crossover study using multiple measures. American Journal of Mental Retardation 106, 525-38.